New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes

Abstract

Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.